Developer docs
API playgroundTry for free, no card

Search company profiles

PrecisePK

Full company profile

uuid000hk2h

Namestring
PrecisePK
Legal namestring
Healthware Inc.
Websiteurl
precisepk.com
Company typeenum
Private
Founded yearint
1986
Descriptiontext

PrecisePK (legally Healthware Inc., a California corporation) is a San Diego-based software company providing model-informed precision dosing (MIPD) and therapeutic drug monitoring for hospitals, health systems, academic medical centers, and government healthcare facilities. Founded in 1986 and formerly operating as TDMS, the company rebranded to PrecisePK in 2024 around a new web-based platform and currently operates with 11–50 employees. The platform uses Bayesian-guided analytics, two-compartment kinetics models, and population pharmacokinetic (PK) priors combined with patient-specific characteristics (age, weight, renal function, serum concentrations) to generate individualized dosing recommendations for 17+ drugs, including Vancomycin (validated by Turner et al. 2018 as least biased), Busulfan, Methotrexate, Cyclosporine, Infliximab, aminoglycosides, and anticonvulsants. Supporting tools include the AKI Prediction Tool for nephrotoxicity monitoring and EHR integration for clinical workflow embedding. The platform is delivered as both a web application and desktop application, available in five languages, with usage claimed across 10+ countries.

PrecisePK generates revenue primarily through annual or multi-year software licensing subscriptions priced per facility/site, with custom enterprise quotes based on hospital size and needs. The company also offers discounted pricing for academic institutions, students, faculty, and GPO (Group Purchasing Organization) members. Go-to-market combines enterprise field sales (targeting hospitals and healthcare institutions with software demonstrations followed by a 60-day free trial) with inside sales handling inbound inquiries via contact forms. The product-led onboarding path allows self-serve trial registration with sales follow-up within 1–2 business days. Customers include named enterprise healthcare providers such as Sharp HealthCare, Dignity Health, VA, Rady Children's Hospital, UCSD Benioff, Sparrow Health System, and Maryland General Hospital, as well as academic institutions including UCSD Skaggs School of Pharmacy, Stony Brook University, and KGI. The company holds SOC 2 Type 2, ISO/IEC 27001:2022, HIPAA, and GDPR certifications, and is hosted on AWS infrastructure. PrecisePK is privately held and founder/management-owned with no disclosed external institutional investors or venture capital funding.

Short descriptiontext

PrecisePK (Healthware Inc.) is a San Diego-based therapeutic drug monitoring software platform providing Bayesian-guided precision dosing recommendations for hospitals, health systems, and academic institutions across 10+ countries, serving 100+ partnerships with 17+ drug models.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic drug monitoring, Bayesian precision dosing, model-informed precision dosing, pharmacokinetic dosing software, vancomycin AUC dosing
Industry2 codes
PRIMARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Therapeutic Drug Monitoring Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software Licensing (Subscription)
TypeSubscription Recurring
Description

Annual or multi-year license subscriptions for healthcare facilities. License is per site/facility. One license allows login on any number of computers within the licensed facility. Pricing is customized based on hospital size, specific needs, and associations.

precisepk.com
2Academic/Nonprofit Pricing
TypeSubscription Recurring
Description

Special pricing programs for students, faculty, academic professionals, and GPO (Group Purchasing Organization) members.

precisepk.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Pricing details3 tiers
1Free Trial - 60-day free trial for qualified institutions
ModelFreemiumBilling cadencePay-as-you-go
Notes

60-day free trial available after software demonstration. Trial requires valid email registration. Demo booking recommended before trial start. Response within 1-2 business days for trial approval.

precisepk.com
2Custom Enterprise License - Hospital/facility pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Flexible and simple pricing plan customized based on hospital's specific needs, size, and associations. License per site. Multi-site purchasing available. Special pricing for GPO members. Quote-based pricing requires contact with sales team.

precisepk.com
3Academic/Nonprofit Pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Special pricing for students, faculty, and academic professionals. Discounted rates for educational and research institutions.

precisepk.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1PreciseRX
Description

Related brand/platform mentioned on the website footer, separate from PrecisePK.

precisepk.com
Core offering1 text field

PrecisePK sells a web-based and desktop therapeutic drug monitoring (TDM) software platform that delivers Bayesian-guided, model-informed precision dosing (MIPD) for hospitals and clinical pharmacists. The platform uses patient-specific characteristics and observed serum concentrations to generate individualized dosing recommendations across a multi-drug model library (vancomycin, aminoglycosides, busulfan, methotrexate, cyclosporine, infliximab, and others), supported by an Acute Kidney Injury (AKI) Prediction Tool and EHR integration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Length of hospital stay reduced up to 10 days using therapeutic drug monitoring system
+4 more records
Product overview1 text field

PrecisePK is a unified therapeutic drug monitoring software platform for model-informed precision dosing (MIPD), formerly known as TDMS. The core platform uses Bayesian-guided analytics and machine learning to provide individualized dosage recommendations. The product portfolio includes specialized drug modules for Vancomycin AUC (the most accurate tool per Turner et al 2018), Busulfan, and the new Methotrexate, Cyclosporine, and Infliximab models for transplant and oncology care. An AKI Prediction Tool provides real-time kidney injury monitoring. The system supports 17 drug models including aminoglycosides, anticonvulsants, and immunosuppressants across neonatal, pediatric, and adult populations. Available as both a web-based SaaS application and downloadable desktop app, with multi-language support and EHR integration capabilities.

Product and service1 record
1PrecisePK Therapeutic Drug Monitoring Platform
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Pacific University Oregon
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-14
Description

Strategic collaboration with Pacific University Oregon to advance precision medicine research and innovation. Announced April 14, 2024, this partnership represents a key academic collaboration to further precision medicine research using PrecisePK's Bayesian dosing technology.

precisepk.com
Strategic tierCoreTypeTechnology or Integration
Description

Cloud infrastructure provider for hosting PrecisePK services. All data is hosted on AWS databases located in the United States. AWS provides the underlying cloud security, networking security, and physical resilience for data centers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

InsightRX is a precision dosing SaaS platform that uses Bayesian PK/PD models to individualize drug dosing for hospitals. It directly competes with PrecisePK in the same clinical use case (vancomycin AUC, aminoglycosides, etc.) and customer base (health system pharmacies).

TypeDirect peer
Description

DoseMeRx is a Bayesian precision dosing platform (acquired by Tabula Rasa HealthCare) offering individualized dosing for vancomycin, aminoglycosides, and other drugs. It competes head-to-head with PrecisePK in hospital pharmacy workflows.

TypeDirect peer
Description

Baysient provides Bayesian-guided therapeutic drug monitoring and dosing analytics software for clinicians, with overlap in vancomycin and other key drug models. It is a focused direct competitor in the same precision dosing niche.

TypeBroad incumbent
Description

Epic is the dominant hospital EHR vendor and increasingly embeds clinical decision support and dosing calculators. While not a focused TDM vendor, its installed base and integration depth represent a long-term competitive threat to standalone TDM tools like PrecisePK.

5Oracle Health (Cerner)
TypeBroad incumbent
Description

Oracle Health (formerly Cerner) provides hospital EHR systems and increasingly integrates drug dosing and clinical decision support. As a broad incumbent, it competes with PrecisePK for hospital budget and workflow ownership.

TypeBroad incumbent
Description

Wolters Kluwer provides clinical decision support, drug information (Lexicomp/Medispan), and surveillance tools used by hospital pharmacists. It is a broader incumbent competing for the same pharmacy IT budget as PrecisePK.

TypeBroad incumbent
Description

FDB supplies drug knowledge bases and clinical decision support that power dosing and screening in many EHRs. It is an adjacent incumbent whose drug content underpins both EHR-embedded dosing and standalone TDM solutions.

TypeEmerging player
Description

Tabula Rasa HealthCare is a pharmacy services and technology company that owns DoseMeRx and offers broader medication safety and pharmacokinetic solutions. It overlaps with PrecisePK through its precision dosing product line.

TypeEmerging player
Description

RxAnte applies analytics and predictive modeling to medication utilization and adherence for health plans and providers. It is an adjacent player whose predictive analytics approach intersects with PrecisePK's model-informed dosing philosophy.

TypeOthers
Description

GlobalRPH is a clinical reference site that independently endorses dosing calculators including PrecisePK's Vancomycin AUC tool. It is an ecosystem/influencer partner rather than a competitor, shaping prescriber awareness of TDM software.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration26 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PrecisePK

Therapeutic Drug Monitoring Softwareprecisepk.com

PrecisePK (Healthware Inc.) is a San Diego-based therapeutic drug monitoring software platform providing Bayesian-guided precision dosing recommendations for hospitals, health systems, and academic institutions across 10+ countries, serving 100+ partnerships with 17+ drug models.

What PrecisePK does

PrecisePK (legally Healthware Inc., a California corporation) is a San Diego-based software company providing model-informed precision dosing (MIPD) and therapeutic drug monitoring for hospitals, health systems, academic medical centers, and government healthcare facilities. Founded in 1986 and formerly operating as TDMS, the company rebranded to PrecisePK in 2024 around a new web-based platform and currently operates with 11–50 employees. The platform uses Bayesian-guided analytics, two-compartment kinetics models, and population pharmacokinetic (PK) priors combined with patient-specific characteristics (age, weight, renal function, serum concentrations) to generate individualized dosing recommendations for 17+ drugs, including Vancomycin (validated by Turner et al. 2018 as least biased), Busulfan, Methotrexate, Cyclosporine, Infliximab, aminoglycosides, and anticonvulsants. Supporting tools include the AKI Prediction Tool for nephrotoxicity monitoring and EHR integration for clinical workflow embedding. The platform is delivered as both a web application and desktop application, available in five languages, with usage claimed across 10+ countries.

PrecisePK generates revenue primarily through annual or multi-year software licensing subscriptions priced per facility/site, with custom enterprise quotes based on hospital size and needs. The company also offers discounted pricing for academic institutions, students, faculty, and GPO (Group Purchasing Organization) members. Go-to-market combines enterprise field sales (targeting hospitals and healthcare institutions with software demonstrations followed by a 60-day free trial) with inside sales handling inbound inquiries via contact forms. The product-led onboarding path allows self-serve trial registration with sales follow-up within 1–2 business days. Customers include named enterprise healthcare providers such as Sharp HealthCare, Dignity Health, VA, Rady Children's Hospital, UCSD Benioff, Sparrow Health System, and Maryland General Hospital, as well as academic institutions including UCSD Skaggs School of Pharmacy, Stony Brook University, and KGI. The company holds SOC 2 Type 2, ISO/IEC 27001:2022, HIPAA, and GDPR certifications, and is hosted on AWS infrastructure. PrecisePK is privately held and founder/management-owned with no disclosed external institutional investors or venture capital funding.

PrecisePK firmographics

Firmographics
Name
PrecisePK
Legal name
Healthware Inc.
Website
https://precisepk.com
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
11–50 employees
Short description
PrecisePK (Healthware Inc.) is a San Diego-based therapeutic drug monitoring software platform providing Bayesian-guided precision dosing recommendations for hospitals, health systems, and academic institutions across 10+ countries, serving 100+ partnerships with 17+ drug models.
Ownership category
akta.pro rank

PrecisePK industry classification

Industry
Product category
Therapeutic Drug Monitoring Software
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Therapeutic drug monitoring
  • Bayesian precision dosing
  • Model-informed precision dosing
  • Pharmacokinetic dosing software
  • Vancomycin AUC dosing

Where PrecisePK is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PrecisePK business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Software Licensing (Subscription): Annual or multi-year license subscriptions for healthcare facilities. License is per site/facility. One license allows login on any number of computers within the licensed facility. Pricing is customized based on hospital size, specific needs, and associations.
  2. Academic/Nonprofit Pricing: Special pricing programs for students, faculty, academic professionals, and GPO (Group Purchasing Organization) members.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree Trial - 60-day free trial for qualified institutions
SubscriptionAnnualCustom Enterprise License - Hospital/facility pricing
SubscriptionAnnualAcademic/Nonprofit Pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

PrecisePK product offering

Product offering

Core offering

PrecisePK sells a web-based and desktop therapeutic drug monitoring (TDM) software platform that delivers Bayesian-guided, model-informed precision dosing (MIPD) for hospitals and clinical pharmacists. The platform uses patient-specific characteristics and observed serum concentrations to generate individualized dosing recommendations across a multi-drug model library (vancomycin, aminoglycosides, busulfan, methotrexate, cyclosporine, infliximab, and others), supported by an Acute Kidney Injury (AKI) Prediction Tool and EHR integration.

Product overview

PrecisePK is a unified therapeutic drug monitoring software platform for model-informed precision dosing (MIPD), formerly known as TDMS. The core platform uses Bayesian-guided analytics and machine learning to provide individualized dosage recommendations. The product portfolio includes specialized drug modules for Vancomycin AUC (the most accurate tool per Turner et al 2018), Busulfan, and the new Methotrexate, Cyclosporine, and Infliximab models for transplant and oncology care. An AKI Prediction Tool provides real-time kidney injury monitoring. The system supports 17 drug models including aminoglycosides, anticonvulsants, and immunosuppressants across neonatal, pediatric, and adult populations. Available as both a web-based SaaS application and downloadable desktop app, with multi-language support and EHR integration capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • PreciseRX: Related brand/platform mentioned on the website footer, separate from PrecisePK.

Products and services

  • PrecisePK Therapeutic Drug Monitoring Platform

Quantifiable outcome

  • Length of hospital stay reduced up to 10 days using therapeutic drug monitoring system
  • +4 more outcomes

Companies that use PrecisePK

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

PrecisePK technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration26 records

AI capability5 records

Feature7 records

PrecisePK partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Pacific University OregoncoreStrategic or Co-development Partner · 14 April 2024Strategic collaboration with Pacific University Oregon to advance precision medicine research and innovation. Announced April 14, 2024, this partnership represents a key academic collaboration to further precision medicine research using PrecisePK's Bayesian dosing technology.
  • AWS (Amazon Web Services)coreTechnology or IntegrationCloud infrastructure provider for hosting PrecisePK services. All data is hosted on AWS databases located in the United States. AWS provides the underlying cloud security, networking security, and physical resilience for data centers.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

PrecisePK competitors and assessment

Company assessment

Direct peers

  • InsightRX: InsightRX is a precision dosing SaaS platform that uses Bayesian PK/PD models to individualize drug dosing for hospitals. It directly competes with PrecisePK in the same clinical use case (vancomycin AUC, aminoglycosides, etc.) and customer base (health system pharmacies).
  • DoseMeRx (Tabula Rasa HealthCare): DoseMeRx is a Bayesian precision dosing platform (acquired by Tabula Rasa HealthCare) offering individualized dosing for vancomycin, aminoglycosides, and other drugs. It competes head-to-head with PrecisePK in hospital pharmacy workflows.
  • Baysient: Baysient provides Bayesian-guided therapeutic drug monitoring and dosing analytics software for clinicians, with overlap in vancomycin and other key drug models. It is a focused direct competitor in the same precision dosing niche.

Broad incumbents

  • Epic Systems: Epic is the dominant hospital EHR vendor and increasingly embeds clinical decision support and dosing calculators. While not a focused TDM vendor, its installed base and integration depth represent a long-term competitive threat to standalone TDM tools like PrecisePK.
  • Oracle Health (Cerner): Oracle Health (formerly Cerner) provides hospital EHR systems and increasingly integrates drug dosing and clinical decision support. As a broad incumbent, it competes with PrecisePK for hospital budget and workflow ownership.
  • Wolters Kluwer (UpToDate / Sentri7): Wolters Kluwer provides clinical decision support, drug information (Lexicomp/Medispan), and surveillance tools used by hospital pharmacists. It is a broader incumbent competing for the same pharmacy IT budget as PrecisePK.
  • First Databank (FDB): FDB supplies drug knowledge bases and clinical decision support that power dosing and screening in many EHRs. It is an adjacent incumbent whose drug content underpins both EHR-embedded dosing and standalone TDM solutions.

Emerging players

  • Tabula Rasa HealthCare: Tabula Rasa HealthCare is a pharmacy services and technology company that owns DoseMeRx and offers broader medication safety and pharmacokinetic solutions. It overlaps with PrecisePK through its precision dosing product line.
  • RxAnte: RxAnte applies analytics and predictive modeling to medication utilization and adherence for health plans and providers. It is an adjacent player whose predictive analytics approach intersects with PrecisePK's model-informed dosing philosophy.

Others

  • GlobalRPH: GlobalRPH is a clinical reference site that independently endorses dosing calculators including PrecisePK's Vancomycin AUC tool. It is an ecosystem/influencer partner rather than a competitor, shaping prescriber awareness of TDM software.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

PrecisePK social profiles

Digital presence

PrecisePK compliance and trust

Trust signal

Compliance4 records

PrecisePK financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PrecisePK leadership team

Management profile

Number of profiles

Profiles1 record

PrecisePK funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PrecisePK M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PrecisePK

What does PrecisePK do?

PrecisePK sells a web-based and desktop therapeutic drug monitoring (TDM) software platform that delivers Bayesian-guided, model-informed precision dosing (MIPD) for hospitals and clinical pharmacists. The platform uses patient-specific characteristics and observed serum concentrations to generate individualized dosing recommendations across a multi-drug model library (vancomycin, aminoglycosides, busulfan, methotrexate, cyclosporine, infliximab, and others), supported by an Acute Kidney Injury (AKI) Prediction Tool and EHR integration.

Is PrecisePK a public or private company?

PrecisePK is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PrecisePK founded?

PrecisePK was founded in 1986. It employs 11 to 50 people.

Where is PrecisePK based?

PrecisePK is headquartered in San Diego, United States, in the North America region.

How does PrecisePK make money?

Two revenue lines are on record. Software Licensing (Subscription) is the primary driver. The others are academic/Nonprofit Pricing.

Who are PrecisePK's main competitors?

Direct peers on record are InsightRX, DoseMeRx (Tabula Rasa HealthCare) and Baysient. Broad incumbents are Epic Systems, Oracle Health (Cerner), Wolters Kluwer (UpToDate / Sentri7) and First Databank (FDB). Emerging players are Tabula Rasa HealthCare and RxAnte. GlobalRPH is listed as an others.

Does PrecisePK have an API?

No public API is recorded for PrecisePK.

What industry is PrecisePK in?

PrecisePK's product category is Therapeutic Drug Monitoring Software. Its primary akta.pro industry code is HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories, with a secondary code of HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePrecisePK Marks 40+ Years of Precision Dosing, Highlights EHR Integrations Driving Safer Pharmacist WorkflowsPrecisePK, a therapeutic drug monitoring software company, highlights its EHR integrations with Epic, Cerner, and Sentri7, built on over 40 years of precision dosing since 1985. The integrations automatically import vancomycin doses, lab values, and patient data, reducing manual entry and errors. The company supports over 20 drug classes and operates in 20+ countries.PR NewswirePrecisePK Redefines Precision Dosing with Academic Integration, Setting New Standards In Therapeutic Drug MonitoringPrecisePK announced its expansion in South America through integration into key healthcare and educational institutions, earning recognition from Chilean educational institution Escuela de Química y Farmacia for its Bayesian Model-Informed Precision Dosing software. The platform covers over 20 medications including vancomycin, busulfan, and tacrolimus, and has established notable clinical partnerships with Clínica Andes Salud Concepción and Servicio de Salud Talcahuano. The endorsement from Escuela de Química y Farmacia represents a strategic alliance aimed at advancing precision medicine education and elevating clinical drug dosing standards in the region.PR NewswirePrecisePK's Bayesian Precision Dosing Solutions Gain Trust of Premier Health System- Setting the Gold Standard for Clinicians in South AmericaPrecisePK announced a two-year partnership with Chilean healthcare institution Clínica Andes Salud Concepción to implement its Bayesian-based Therapeutic Drug Monitoring (TDM) software. The collaboration aims to transition the clinic from weight-based calculators to model-informed precision dosing, optimizing clinical treatments and ensuring compliance with Vancomycin AUC Guidelines. This agreement follows similar successful adoptions by other Chilean hospitals and universities, highlighting the software's role in improving patient care and reducing costs.PR NewswirePortugal's Health Systems Achieve Breakthrough with PrecisePK's Bayesian Precision Dosing, Pioneering Personalized CarePrecisePK announced its selection by Luisadas Saude Health (LSHS) to implement Bayesian precision dosing technology at Hospital de Cascais, marking the second Portuguese health system to adopt the technology following Unidade de Saúde Local da Guarda (ULSG). The implementation enables data-driven, personalized medication dosing with real-time bedside antibiotic recommendations, particularly for vancomycin monitoring. The partnership aims to advance antimicrobial stewardship and precision medicine adoption across Portugal's healthcare system.PR NewswirePrecisePK Celebrates 30 Years of Bayesian Precision Dosing Partnership With UC San Diego Health, Leading Other UC Hospitals To FollowPrecisePK is celebrating the 30th anniversary of its partnership with UC San Diego Health, marking three decades of collaboration on Bayesian precision dosing technology for therapeutic drug monitoring. The partnership, which has expanded to include other UC hospitals totaling nine sites, played a key role in transitioning healthcare providers from trough-based to AUC-based vancomycin dosing following 2020 guideline changes from major pharmacy and infectious diseases societies. Some UC sites are now extending the technology beyond vancomycin to other therapeutic areas including aminoglycosides, oncology, and organ transplant, with potential to improve patient safety and cancer survival rates.PR NewswireKern Medical Chooses PrecisePK to Provide Bayesian Precision Dosing SolutionsPrecisePK announced that Kern Medical has implemented its Bayesian AUC-based precision dosing software for vancomycin and other antibiotics, replacing traditional formula-driven calculations with personalized dosing tools. The adoption aligns with 2020 consensus guidelines from major medical societies recommending AUC/MIC ratio monitoring for optimal vancomycin efficacy and patient safety. PrecisePK's CEO noted the partnership will help develop solutions tailored to the California population while supporting Kern Medical's antimicrobial stewardship initiatives.PR NewswireScandinavia's Largest Hospital Becomes Second Institution in Norway to Adopt PrecisePK's Bayesian Dosing SoftwarePrecisePK has announced a partnership with Oslo University Hospital (OUS), Scandinavia's largest hospital, making OUS the second Norwegian health institution to adopt PrecisePK's Bayesian model-informed precision dosing (MIPD) software, following the University Hospital of North Norway. OUS will implement the technology for therapeutic drug monitoring of drugs including busulfan, tacrolimus, vancomycin, and aminoglycosides, replacing in-house applications. The partnership aims to enhance patient safety by minimizing drug toxicity and adverse events while consolidating OUS's clinical services to the highest standard of care for model-informed precision dosing.PR NewswireDrug Reference Made Easy with Sanford Guide Accessible within PrecisePKPrecisePK and Sanford Guide announced a partnership to integrate Sanford Guide's infectious disease treatment guidelines into the PrecisePK clinical decision support platform. The integration aims to make clinical guidelines more accessible to healthcare providers at the point of care, supporting evidence-based dosing practices amid growing antibiotics resistance concerns. Executives from both companies framed the collaboration as a way to improve pharmacovigilance and give clinicians more time with patients.PR NewswirePrecisePK Collaborates with Wolters Kluwer to Enhance Dose OptimizationPrecisePK announced a collaboration with Wolters Kluwer to integrate its model-informed precision dosing (MIPD) software into the Sentri7 Pharmacy platform, launching in early 2023. The integrated solution will provide Bayesian dosing support for vancomycin and over 20 additional medications, incorporating 2020 therapeutic monitoring guidelines from the American Society of Health-System Pharmacists and the Infectious Diseases Society of America. The partnership aims to help hospitals improve patient safety, clinical outcomes, and simplify clinician workloads through real-time AKI monitoring and predictive analytics.